Citadel Advisors
NRIX icon

Citadel Advisors’s Nurix Therapeutics NRIX Stock Holding History

Citadel Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$567K Buy
36,600
+2,600
+8% +$43.1K ﹤0.01% 9000
2025
Q4 		$645K Buy
34,000
+4,800
+16% +$69K ﹤0.01% 8401
2025
Q3 		$270K Sell
29,200
-10,800
-27% -$112K ﹤0.01% 10600
2025
Q2 		$456K Buy
40,000
+34,200
+590% +$370K ﹤0.01% 8856
2025
Q1 		$68.9K Sell
5,800
-24,000
-81% -$401K ﹤0.01% 11940
2024
Q4 		$561K Buy
29,800
+13,500
+83% +$309K ﹤0.01% 8304
2024
Q3 		$366K Buy
16,300
+6,600
+68% +$150K ﹤0.01% 8892
2024
Q2 		$202K Buy
9,700
+8,500
+708% +$132K ﹤0.01% 9915
2024
Q1 		$17.6K Sell
1,200
-10,900
-90% -$117K ﹤0.01% 13093
2023
Q4 		$125K Buy
12,100
+5,800
+92% +$39.8K ﹤0.01% 10659
2023
Q3 		$49.5K Sell
6,300
-118,600
-95% -$1.08M ﹤0.01% 11773
2023
Q2 		$1.25M Sell
124,900
-27,800
-18% -$283K ﹤0.01% 6004
2023
Q1 		$1.36M Buy
152,700
+9,600
+7% +$100K ﹤0.01% 6122
2022
Q4 		$1.57M Buy
143,100
+62,600
+78% +$755K ﹤0.01% 5943
2022
Q3 		$1.05M Sell
80,500
-31,600
-28% -$500K ﹤0.01% 6887
2022
Q2 		$1.42M Buy
112,100
+25,000
+29% +$283K ﹤0.01% 6236
2022
Q1 		$1.22M Buy
87,100
+77,100
+771% +$1.37M ﹤0.01% 7247
2021
Q4 		$290K Buy
10,000
+3,200
+47% +$97K ﹤0.01% 11002
2021
Q3 		$204K Buy
+6,800
New +$210K ﹤0.01% 11948

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Citadel Advisors's NRIX Position: Q1 2026 in Review

Citadel Advisors increased its Nurix Therapeutics (NRIX) stake by 17% in Q1 2026, buying an estimated $3.16M and bringing the position to 1,343,700 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Citadel Advisors first reported a position in NRIX in Q3 2020 and has held it in 21 quarters since. The position peaked at $34.4M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Citadel Advisors held 1,343,700 shares of Nurix Therapeutics worth $20.8M as of Q1 2026.
  • Citadel Advisors bought 190,770 Nurix Therapeutics shares in Q1 2026, an estimated $3.16M.
  • Nurix Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2295 holding.
  • Citadel Advisors first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Nurix Therapeutics position peaked at $34.4M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.